Novo Nordisk files for regulatory approval in the US of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetesGlobeNewsWire • 01/20/21
Novo Nordisk: Poised To Profit As The Lockdowns Make The Obesity Crisis WorseSeeking Alpha • 01/19/21
Novo Nordisk A/S (NVO) CEO Lars Jørgensen Presents at 39th Annual JPMorgan Virtual Healthcare Conference (Transcript)Seeking Alpha • 01/12/21
Novo Nordisk extends COVID-19 Patient Assistance Program, encourages people facing affordability challenges to visit NovoCare.comPRNewsWire • 01/04/21
Best Buys For 2021: Don't Choose The Usual U.S. Suspects, Buy Those European Champions InsteadSeeking Alpha • 01/04/21
Novo Nordisk files for EU regulatory approval of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetesGlobeNewsWire • 12/29/20
Novo Nordisk files for EU regulatory approval of once-weekly semaglutide 2.4 mg for weight managementGlobeNewsWire • 12/18/20
Novo Nordisk to enter phase 3 development in Alzheimer's disease with oral semaglutideGlobeNewsWire • 12/16/20
Novo Nordisk Completes Acquisition of Emisphere Technologies for $1.35 BillionGlobeNewsWire • 12/08/20
Novo Nordisk files for US FDA regulatory approval of once-weekly semaglutide 2.4 mg for weight managementGlobeNewsWire • 12/04/20
EMISPHERE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Emisphere Technologies, Inc. - EMISBusiness Wire • 12/03/20
Novo Nordisk A/S (NVO) CEO Lars Jørgensen on ESG Conference Call - TranscriptSeeking Alpha • 11/30/20